Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Infliximab subcutaneous injection (ATC L04AB02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 125 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab zur subkutanen Injektion (ATC-Code nach WHO: L04AB02)

30/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

40 / 100

Facteurs de risque

No guaranteed purchase quantities; revenue depends on prescription behavior of doctors and dispensing by pharmacies.

Buyer may terminate open-house procedure early if exclusive discount agreements are signed, which historically occurs 8...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Non-exclusive discount agreements for Infliximab subcutaneous injection (ATC L04AB02)
  • Open-house model: any eligible pharmaceutical entrepreneur can participate without exclusivity
Afficher le résumé complet

This is a non-exclusive drug discount agreement under §130a(8) SGB V for the active substance Infliximab for subcutaneous injection (ATC L04AB02). The agreement is offered through an open-house model, allowing any eligible pharmaceutical entrepreneur to conclude a discount agreement with AOK PLUS for insured patients in Saxony and Thuringia. The contract runs until 31 December 2026, with no guaranteed purchase volumes and a possibility of early termination if exclusive agreements are signed. The procedure is voluntarily published and not a formal public procurement under EU directives.

Risques

No guaranteed purchase quantities; revenue depends on prescription behavior of doctors and dispensing by pharmacies.

Buyer may terminate open-house procedure early if exclusive discount agreements are signed, which historically occurs 8...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with a registered office in Germany, EU, or EEA

Eligibility

  • Submission of self-declaration on absence of exclusion grounds per §§123,124 GWB

Administrative

  • Submission of self-declaration on EU Russia sanctions (Regulation (EU) 2022/576)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; all eligible participants are accepted in this open-house model.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Infliximab subcutaneous injection (ATC L04AB02)

Conclusion of non-exclusive discount agreements for the supply of Infliximab subcutaneous injection to AOK PLUS. The open-house model allows any eligible pharmaceutical company to participate. No minimum volumes are guaranteed, and the agreement ends 31 December 2026. Submission is possible on a rolling basis starting from 3 December 2024.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Dec 2024 - Dec 2026

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; all eligible participants are accepted in this open-house model.

Détails de la procédure

Date de publication
10 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
684145-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30